For severe hypoglycemia,
there is no such thing as
a no‑risk patient1

Co-prescribe glucagon with every insulin prescription

All patients on insulin have a chance
of experiencing severe hypoglycemia2
~1 in 3
T1D patients
experience up to
3 events/year3
1 in 5
T2D patients
experience approx.
1 event/year4
Severe hypoglycemia
is associated with a
3.4x
increased
risk of death5*
*At 5 years compared with those who reported either no or mild symptoms of hypoglycemia.

Glucagon is the primary recommended
therapeutic treatment for severe hypoglycemia6

American Diabetes
Association
The American Diabetes Association (ADA)
recommends glucagon for all patients at risk
of level 2 or 3 hypoglycemia6

Gvoke HypoPen® (glucagon injection) autoinjector
Your patients deserve to confidently treat severe hypoglycemia

Anyone can administer Gvoke in 2 simple
steps7,8

Pull red cap off of the Gvoke HypoPen®.
1

Pull red

cap off

Push yellow end into upper arm, lower stomach, or outer thigh; wait 5 seconds for the window to turn red.
2

Push yellow

end down on skin and hold 5 seconds. Window will turn red.

Administer into upper arm, stomach, or thigh.

After using Gvoke, turn person on their side if they are passed out or seizing. Call for emergency help.7

Watch videos
Watch the Instructional Video for Gvoke HypoPen®
Request a Product Demo

Patients and caregivers were able to safely and effectively administer Gvoke HypoPen as demonstrated in 2 clinical studies.

Pull cap straight off the syringe.
1

Prepare

Pull cap straight off the syringe.

Pinch the skin of the upper arm, lower stomach, or outer thigh and insert the needle at a 90-degree angle. Push the plunger down as far as it will go.
2

Inject

Pinch the skin and insert the needle at a 90‑degree angle. Push the plunger down as far as it will go.

Inject into upper arm, stomach, or thigh.

After using Gvoke, turn person on their side if they are passed out or seizing. Call for emergency help.7

Patients and caregivers were able to safely and effectively administer Gvoke HypoPen as demonstrated in 2 clinical studies.

Gvoke HypoPen

In a functional efficacy study

Gvoke HypoPen® (glucagon injection)

99%

of participants (74/75) were able to successfully administer Gvoke HypoPen7,8†

Objective:
To assess if Gvoke could be safely and effectively administered by the appropriate user groups and to assess the effectiveness of product labeling.

Untrained participants:
Given time to familiarize themselves as desired with the device, IFU and Label Guide.

Trained participants:
Introduced to the purpose, dosing and details of the device and procedure, provided time to review the IFU, Label Guide and device, and were given a verbal walk‑through of the device.

All participants returned ~1 week later.

Glucagon Emergency Kit

In a comparative usability study

Traditional glucagon kit

31%a

of participants (5/16) were able to successfully administer a traditional glucagon emergency kit8†

Objective:
To evaluate the ease of use of Gvoke HypoPen versus the traditional glucagon kits that require mixing in a comparative usability study.

Untrained participants:
Did not receive any form of training.

Trained participants:
Received training from the moderator on how to prepare and administer a glucagon injection, an overview of the device and a verbal walk-through of the procedure.

aIn the usability study, 88% (14) successfully administered a rescue injection using the glucagon auto injector versus 31% (5) using glucagon emergency kits (P<0.05). Results from this study were used to inform the final Gvoke HypoPen Instructions for Use, which was evaluated in the summative human factors validation study.

†Administering glucagon in simulated emergencies.

References: 1. Mayo Foundation for Medical Education and Research. (2021, February 1). Insulin (Parenteral Route) Side Effects. Mayo Clinic. https://www.mayoclinic.org/drugs-supplements/insulin-parenteral-route/side-effects/drg-20069501. Accessed May 13, 2021. 2. Perlmuter LC, Flanagan BP, Shah PH, Singh SP. Glycemic control and hypoglycemia. Is the loser the winner? Diabetes Care. 2008;31(10):2072-2076. 3. International Hypoglycemia Study Group. Minimizing Hypoglycemia in Diabetes. Diabetes Care. 2015;38:1583-1591. 4. Edridge CL, Dunkley AJ, Bodicoat DH, et al. Prevalence and Incidence of Hypoglycaemia in 532,542 People with Type 2 Diabetes on Oral Therapies and Insulin: A Systematic Review and Meta-Analysis of Population Based Studies. PLoS ONE. 2015;10(6): e0126427. 5. Newswanger B, Prestreleski S, Andre AD. Human factor studies of a prefilled syringe with stable liquid glucagon in a simulated severe hypoglycemia rescue situation. Expert Opin Drug Deliv. 2019;16(9):1015-1025. 6. American Diabetes Association. Glycemic targets: Standards of medical care in diabetes—2021. Diabetes Care. 2021;44(suppl 1):S73-S84. 7. Gvoke [prescribing information]. Chicago, IL: Xeris Pharmaceuticals, Inc; 2021. 8. Valentine V, Newswanger B, Prestrelski S, Andre AD, Garibaldi M. Human factors usability and validation studies of a glucagon autoinjector in a simulated severe hypoglycemia rescue situation. Diabetes Technol Ther. 2019;21(9):522-530.

Go to:

GLUCAGON GUIDELINES
Sign up for more information Request a Demo Device Contact a Representative